Johns Hopkins team finds how a gut bacterium toxin attacks the colon and drives cancer
Researchers identified claudin-4 as the docking point for a Bacteroides fragilis toxin tied to colon cancer, and a decoy molecule protected mice from its damage.
Summary
Colorectal cancer risk is shaped partly by the bacteria living in our gut. Johns Hopkins researchers have solved a nearly two-decade-old puzzle about how one common species, Bacteroides fragilis, can contribute to it. Some strains make a toxin called BFT that breaks down E-cadherin, a protein that holds colon cells together and keeps the gut lining intact. Until now, no one knew how the toxin first latched onto colon cells. Using CRISPR gene editing, the team found that a protein called claudin-4 serves as the toxin's docking point. They then built a molecular decoy that intercepts BFT before it can do harm, and it protected mice from the toxin's effects. About 20% of healthy people carry B. fragilis, and carrying it does not mean cancer will develop. The work, published in Nature, is early preclinical research, but it points to new ways to detect and prevent bacteria-linked colon damage.
Detailed Summary
Colorectal cancer is one of the leading cancers worldwide, and growing evidence suggests that gut bacteria help shape who develops it. Researchers at the Johns Hopkins Kimmel Cancer Center have now filled a long-standing gap in understanding how one common gut microbe, Bacteroides fragilis, can promote tumor formation.
B. fragilis lives in the intestines of up to 20% of healthy people. Only certain strains make the B. fragilis toxin, or BFT. A 2009 study from senior author Cynthia Sears and colleagues showed that BFT promotes colon tumors in mice. Later work showed that it cleaves E-cadherin, a protein that keeps colon cells tightly joined and maintains the protective barrier. The puzzle was that BFT did not seem to bind E-cadherin directly, so its true receptor remained unknown despite repeated attempts to find it.
In a study published in Nature, the team used CRISPR gene editing to disable genes one by one and see which were needed for the toxin to act. This identified claudin-4 as the essential docking point for BFT. The researchers then used the finding to design a molecular decoy that intercepts the toxin before it reaches colon cells. In mice, the decoy protected against the toxin's harmful effects.
The practical implications are still some way off. The discovery could eventually support new tests to detect toxin-related risk, therapies that block the toxin, or strategies to protect the gut barrier in people who carry toxin-producing strains. Sears also notes that the findings may be relevant to diarrheal illness and bloodstream infections linked to these bacteria.
There are important caveats. The decoy has been tested only in mice, and no human trials have been reported. Carrying B. fragilis does not mean a person will develop cancer, and many other factors, including diet, genetics, and inflammation, contribute to colorectal cancer risk. Readers should not expect a clinical product soon, and the full paper should be consulted for experimental detail.
Key Findings
- Claudin-4 was identified as the essential docking receptor that lets B. fragilis toxin (BFT) attach to colon cells.
- BFT breaks down E-cadherin, weakening the colon's protective barrier and driving inflammation and tumor growth.
- A molecular decoy intercepted BFT and protected mice from the toxin's harmful effects.
- Up to 20% of healthy people carry B. fragilis, but only some strains produce the toxin.
- CRISPR gene-editing screens solved a receptor mystery that had resisted earlier attempts for nearly two decades.
Methodology
This is a university press-release news report on a peer-reviewed study in Nature, using CRISPR-based screening and mouse experiments. Johns Hopkins is a highly credible source, but press releases tend to emphasize breakthroughs. The evidence is preclinical, and the article gives few experimental details.
Study Limitations
The decoy was tested only in mice, and it is unknown whether it is safe or effective in humans. The article does not say how strongly toxin-producing strains raise colorectal cancer risk in people. Check the Nature paper for sample sizes, mouse models, and any claims about causation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: